Nanobac Pharmaceuticals, Incorporated
NNBP · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Revenue | $18 | $225 | $657 | $358 |
| % Growth | -92.2% | -65.7% | 83.3% | – |
| Cost of Goods Sold | $15 | $80 | $229 | $100 |
| Gross Profit | $3 | $145 | $427 | $258 |
| % Margin | 17.6% | 64.5% | 65.1% | 72% |
| R&D Expenses | $1,149 | $1,995 | $1,194 | $2,375 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,308 | $1,839 | $1,312 | $4,766 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,918 | $4,960 | $3,265 | $7,858 |
| Operating Income | $4,915 | $4,815 | $2,838 | $7,600 |
| % Margin | 27,891.8% | 2,139% | 432% | 2,120.9% |
| Other Income/Exp. Net | -$1,661 | -$744 | -$850 | -$217 |
| Pre-Tax Income | -$6,576 | -$4,973 | -$3,687 | -$7,818 |
| Tax Expense | $1,661 | $159 | $850 | $274 |
| Net Income | -$6,576 | -$4,973 | -$3,687 | -$7,875 |
| % Margin | -37,319.7% | -2,209.5% | -561.4% | -2,197.4% |
| EPS | 0 | -0.025 | -0.02 | -0.052 |
| % Growth | 100% | -27.7% | 62.1% | – |
| EPS Diluted | 0 | -0.025 | -0.02 | -0.052 |
| Weighted Avg Shares Out | 0 | 199,425 | 188,859 | 152,903 |
| Weighted Avg Shares Out Dil | 0 | 199,425 | 188,859 | 152,903 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $460 | $541 | $760 | $717 |
| EBITDA | -$5,929 | -$4,233 | -$2,857 | -$6,883 |
| % Margin | -33,646.8% | -1,880.6% | -434.9% | -1,920.8% |